QuidelOrtho shares jumped after a report that the company may be exploring a sale of its point-of-care (POC) testing business. The Financial Times cited people familiar with the matter saying bids are being sought for the unit that includes rapid antigen tests for respiratory viruses and cardiac-related conditions, with a target valuation cited around $1.5 billion. The deal proceeds, according to the report, could be used to offset net debt tied to QuidelOrtho’s 2021 acquisition of Ortho Clinical Diagnostics. QuidelOrtho did not confirm the rumor, with a company spokesperson saying it declines to comment on speculation, while reiterating that priorities and operations remain unchanged. The report follows a first-quarter revenue miss that triggered a reduced outlook and additional operational changes, as well as recent moves including the April acquisition of Lex Diagnostics and its Velo rapid point-of-care PCR diagnostic system. QuidelOrtho is also exiting its donor screening business. If executed, a POC asset sale would also change the revenue mix and may reduce exposure to seasonal respiratory swings—though it could also shift margins depending on which businesses remain.